Guerbet Names Karim Boussebaa as CEO Amid Strategic Pivot
Event summary
- Karim Boussebaa appointed CEO of Guerbet effective February 2, 2026.
- Boussebaa brings 25+ years of healthcare and medical technology experience.
- Former interim CEO Jérôme Estampes returns to role as CFO and SVP Business Development.
- Guerbet reported €841 million in revenue for 2024.
The big picture
Guerbet’s appointment of Karim Boussebaa as CEO underscores the company’s push to strengthen operational and strategic management amid a demanding market environment. The move comes as medical imaging and MedTech sectors face increasing pressure to innovate and adapt to technological advancements. With €841 million in revenue for 2024, Guerbet’s strategic direction under Boussebaa will be critical to sustaining its position as a global leader in contrast agents and medical imaging solutions.
What we're watching
- Execution Risk
- How Boussebaa’s transformation and innovation experience will translate into Guerbet’s operational performance.
- Market Adaptation
- The pace at which Guerbet can adapt to a rapidly evolving medical imaging market under new leadership.
- Strategic Focus
- Whether Boussebaa will prioritize growth, innovation, or operational efficiency in his new role.
Related topics